Myeloid Neoplasm

DNMT3A R882 mutation was associated with reduced relapse free and overall survival in ELN-unfavorable, cytogenetically normal AMLs.

PMID 23632886 · Gaidzik et al., 2013 · Open in CIViC

Therapy-related AML was less common in patients with DNMT3A mutations (64.5% of which were R882) than patients wildtype for DNMT3A in a large cohort of younger (18-60) AML patients.

PMID 23632886 · Gaidzik et al., 2013 · Open in CIViC

DNMT3A mutations (64.5% R882) were associated with older age, higher white blood cell count and cytogenetically normal AML in a large cohort of younger (18-60) AML patients.

PMID 23632886 · Gaidzik et al., 2013 · Open in CIViC

DNMT3A R882 mutations were associated with cytogenetically normal AML in a large cohort of younger (18-60) AML patients.

PMID 23632886 · Gaidzik et al., 2013 · Open in CIViC

DNMT3A mutations were associated with achievement of complete remission in a large cohort of younger (18-60) AML patients.

PMID 23632886 · Gaidzik et al., 2013 · Open in CIViC

Complete remission rate was not different between young AML patients (<60 years old) with or without DNMT3A mutations (60% of which were R882).

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

Young AML patients (415 patients; <60 years old) with DNMT3A R882 mutations (n=58) have shorter overall and relapse-free survival than patients with wildtype DNMT3A.

PMID 22490330 · Ribeiro et al., 2012 · Open in CIViC

DNMT3A R882 mutations occur most often in de novo AML patients with intermediate risk cytogenetics (39/194 intermediate risk patients vs 0/89 low and high risk).

PMID 22081665 · LaRochelle et al., 2011 · Open in CIViC

DNMT3A mutations (59% of which were R882) were associated with intermediate risk cytogenetics (including normal karyotype) and not favorable risk cytogenetic abnormalities (PML::RARA, RUNX1::RUNX1T1, … (full text at CIViC)

PMID 21067377 · Ley et al., 2010 · Open in CIViC

Daunorubicin treatment resulted in similar overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.

PMID 22081665 · LaRochelle et al., 2011 · Open in CIViC

Idarubicin increases the overall survival and disease free survival in de novo AML patients with DNMT3A R882 mutation compared to those who do not harbor this mutation.

PMID 22081665 · LaRochelle et al., 2011 · Open in CIViC

DNMT3A R882P somatic mutation, together with R882H, R882C and R882S were identified from Acute Myeloid Leukemia (AML) patients. And R882P, R882H and R882C were revealed as significant hotspot mutation… (full text at CIViC)

PMID 21067377 · Ley et al., 2010 · Open in CIViC

In an in vitro kinase study, the recombinant ABL1 M351T mutant kinase did not demonstrate resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 2 and 0) when compared to wil… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In this study, 18 patients with PCM1-JAK2 (n = 8), BCR-JAK2 (n = 1), and ETV6-ABL1 (n = 9) fusion genes were enrolled. RT-PCR was performed for confirmation of PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion… (full text at CIViC)

PMID 32279331 · Schwaab et al., 2020 · Open in CIViC

The HT93A cell line was established from a patient with acute myelogenous leukemia (AML-M3). The patient was a 66 yr old man and was successfully induced to first and second remission with combined ch… (full text at CIViC)

PMID 10706884 · Iijima et al., 2000 · Open in CIViC

PKC412 inhibited the growth of TEL-FGFR3 fusion-transformed Ba/F3 cells by 25% at 100 nM, 45% at 200 nM, and 85% at nM in the absence of interleukin 3. The N540D mutation in the context of FGFR3 was i… (full text at CIViC)

PMID 16091734 · Chen et al., 2005 · Open in CIViC

In a study of 439 patients with myelodysplastic syndrome, patients with ETV6 mutations (N=12) has worse overall survival than wildtype patients (N=427) (P=0.05 univariate). This difference was also ob… (full text at CIViC)

PMID 21714648 · Bejar et al., 2011 · Open in CIViC

Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. I… (full text at CIViC)

PMID 29920189 · Taylor et al., 2018 · Open in CIViC

Two AML cell lines, IMS-M2 and M0-91, with the ETV6-NTRK3 fusion were treated with entrectinib. Sequencing of these cell lines found no other driver mutations in 265 other cancer genes suggesting the… (full text at CIViC)

PMID 29237803 · Smith et al., 2018 · Open in CIViC

In myelodysplastic syndrome, patients with point mutations in EZH2 have worse overall survival that their wild-type counterparts.

PMID 20601954 · Nikoloski et al., 2010 · Open in CIViC

In a study of 439 patients with myelodysplastic syndrome, patients with EZH2 mutations (N=10) has worse overall survival than wildtype patients (N=429) (P=0.02 univariate). This difference was also ob… (full text at CIViC)

PMID 21714648 · Bejar et al., 2011 · Open in CIViC

AML MOLM14 cells were cocultured with FLT3 inhibitor AC220 (10 nM) and selected proteins expressed in the bone marrow microenvironment. FL and FGF2 were the only proteins that increased viability >2 s… (full text at CIViC)

PMID 27671675 · Traer et al., 2016 · Open in CIViC

In this preclinial trial, the AML cell line KG1 with FGFR1OP2-FGFR1 mutation was treated with Ponatinib. This drug effectively inhibits both FGFR phosphorylation and viability for KG1 cells at IC50 va… (full text at CIViC)

PMID 21482694 · Gozgit et al., 2011 · Open in CIViC

In an in vitro kinase study, the recombinant FGFR1 V561M mutant kinase demonstrated resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 87 and 41) when compared to wild ty… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In an in vitro kinase study, the recombinant FGFR1 V561M mutant kinase demonstrated resistance to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 100 and 64) when compared to wild t… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In an in vitro kinase study, the recombinant FGFR2 N549H mutant kinase demonstrated sensitivity to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 32 and 3) when compared to wild ty… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

In an in vitro kinase study, the recombinant FGFR2 N549H mutant kinase demonstrated sensitivity to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 6 and -1) when compared to wild ty… (full text at CIViC)

PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

Preclinical study of FGFR Inhibitors AZ12908010, PD173074 and AZD4547 in cancer cell lines. Cell lines with aberrant FGFR signalling were more sensitive to FGFR Inhibition. Sequencing of a myeloma cel… (full text at CIViC)

PMID 22869148 · Chell et al., 2013 · Open in CIViC

In this phase II, open-label, non-randomized trial, 36 patients with the myeloproliferative neoplasms chronic eosinophilic leukemia, CEL (n = 23) and hypereosinophilic syndrome, HES (n = 13) were enro… (full text at CIViC)

PMID 18950453 · Metzgeroth et al., 2008 · Open in CIViC

Of eleven patients prospectively accrued with hypereosinophilic syndrome, nine had favorable responses to imatinib that lasted >3 months post-treatment. Of these nine patients, five were found to have… (full text at CIViC)

PMID 12660384 · Cools et al., 2003 · Open in CIViC

In an in vitro study, a Ba/F3 cell line stably expressing the T674I mutation in the PDGFRA portion of the FIPL1-PDGFRA fusion protein was found to have reduced sensitivity to dasatinib treatment (IC50… (full text at CIViC)

PMID 19212337 · Lierman et al., 2009 · Open in CIViC

One patient with FIP1L1/PDGFRA-positive CEL was identified as developing secondary resistance to imatinib. A PDGFRA T674I mutation was identified in the tyrosine kinase domain. Salvage therapy with ni… (full text at CIViC)

PMID 21818111 · Metzgeroth et al., 2012 · Open in CIViC

A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D593del using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FL… (full text at CIViC)

PMID 28077790 · Nguyen et al., 2017 · Open in CIViC

A panel of 13 FLT3 tyrosine kinase inhibitors was tested against Ba/F3 cells transfected with FLT3 D593del using MTT growth/survival assay, and results were compared to Ba/F3 cells transfected with FL…

In a study of 82 newly diagnosed myelodysplastic syndrome (MDS) patients followed through to progression to acute myeloid leukemia (AML) (n =70), the incidence of FLT3 (ITD, TKD) and NRAS mutations at… (full text at CIViC)

PMID 14737077 · Shih et al., 2004 · Open in CIViC

In a Phase 1-2 trial of patients with relapsed / refractory AML, patients were enrolled in 7 dose-escalation or dose-expansion cohorts. Gilteritinib monotherapy was well tolerated, generated high resp… (full text at CIViC)

PMID 28645776 · Perl et al., 2017 · Open in CIViC